Bayer expands men’s healthcare portfolio
Licence agreement for innovative testosterone gel also covers emerging markets
Berlin – Bayer Schering Pharma will develop and commercialise ProStrakan’s Tostrex® in Canada, Latin America, the Middle East, Africa, Asia and the Pacific region. A respective agreement between Bayer Schering Pharma and ProStrakan Group plc. was signed which grants Bayer exclusive marketing rights in these regions.
Tostrex is indicated for testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical symptoms and biochemical analyses. Tostrex is a 2% testosterone gel presented in a canister with a metered pump.
“Adding Tostrex to our portfolio will strengthen our transdermal testosterone portfolio within the therapeutic business area of Men’s Healthcare in emerging markets,” said Jean-Philippe Milon, Head of Bayer Schering Pharma’s Business Unit General Medicine.
Bayer already offers Levitra® for the treatment of erectile disfunction as well as testosterone therapies with Nebido® and Testogel® in the Men´s Healthcare portfolio. Levitra and Nebido are marketed in most countries globally exept the US and Testogel in Western Europe and Australia. Erectile Dysfunction (ED) and Testosterone Deficiency Syndrome (TDS) are men’s health problems that have both a physical and psychological impact on the patient.
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women’s Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at www.bayerscheringpharma.de.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.